RxDoctor Payments Data

Maria Desancho, MD

Hematology · New York, NYNPI 1730269374

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (51.4%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. Pharmacosmos Therapeutics Inc. accounts for 84.9% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2024 at $18,505 and has fallen 99.4% since, to $109 in 2025.

$41,361in general payments, 2019–2025

Across 17 payments — averaging $2433.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pharmacosmos Therapeutics Inc.$35K
  • Sanofi$6K
  • Pfizer$200
  • Genentech USA, Inc.$186
  • Bio Products Laboratory USA, Inc.$130
  • Bayer$108
  • plus $77 from 2 others
$380,437in research payments, 2019–2025

Across 62 payments — averaging $6136.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$191K
  • Incyte Corporation$62K
  • Swedish Orphan Biovitrum AB$56K
  • Sanofi US Services Inc.$50K
  • Vertex$21K

What the payments were for

  • Consulting fees$9,14322%
  • Speaking & faculty fees$10,00024%
  • Travel & lodging$21,27651%
  • Food & beverage$9422%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pharmacosmos Therapeutics Inc.5$35,131
Sanofi3$5,529
Pfizer2$200
Genentech USA, Inc.2$186
Bio Products Laboratory USA, Inc.1$130
Bayer1$108
Bristol Myers Squibb2$44
Shire North American Group Inc1$33

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$41,361 in reported general payments places this provider in the 85th percentile of 157 hematology providers in New York.

See all hematology providers in New York

Medicare billing

Part B allowed, 2024
$41,353
Medicare patients
174
Services billed
270

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban28$24,658
EliquisApixaban17$17,030

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$200$17,03017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 157 hematology providers in New York.

Other hematology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →